Hemab Therapeutics

Summary ipo Updated Apr 30, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Cambridge, MA / Copenhagen, Denmark
Founded 2020
Latest Stage IPO
Total Raised $458.5M+
Website https://hemab.com
Sector
biotech rare-disease hematology

Investors

Third Rock Ventures series-c (2025)

Founders

Benny Sorensen CEO

About

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing prophylactic and on-demand therapies for serious and underserved bleeding and clotting disorders 1. The company is dual-headquartered in Cambridge, Massachusetts and Copenhagen, Denmark, and is led by CEO Benny Sorensen, MD, PhD 1. Its pipeline includes sutacimig for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002 for von Willebrand disease 1.

Funding History

Date Round Amount Lead Co-investors
2025-10-27 Series C $157M Sofinnova Partners Avoro Capital Advisors, RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, Rock Springs Capital 1
2026-04-30 IPO $301.5M Goldman Sachs (bookrunner) Jefferies, Evercore ISI, Wedbush PacGrow 23

The company priced its upsized initial public offering of 16,750,000 shares at $18.00 per share on April 30, 2026, for gross proceeds of approximately $301.5 million 2. Common stock began trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker symbol “COAG” 2. Underwriters were granted a 30-day option to purchase up to an additional 2,512,500 shares 2.

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. Hemab Therapeutics, “Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders,” October 27, 2025. Accessed April 2026. https://www.hemab.com/news-items/hemab-therapeutics-announces-157-million-series-c-financing-to-advance-next-generation-treatments-for-underserved-bleeding-disorders↩↩↩↩

  2. GlobeNewswire, “Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering,” April 30, 2026. Accessed April 2026. https://www.globenewswire.com/news-release/2026/04/30/3285621/0/en/Hemab-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html↩↩↩↩

  3. Bloomberg, “Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO,” April 27, 2026. Accessed April 2026. https://www.bloomberg.com/news/articles/2026-04-27/novo-backed-biotech-hemab-seeks-to-raise-212-million-in-us-ipo↩